Background: Endocannabinoids (ECs) modulate both excitatory and inhibitory components in the CNS. There is a growing body of evidence that shows ECs influence both hypothalamic orexinergic and histaminergic neurons involved in narcolepsy physiopathology. Therefore, ECs may influence sleep and sleep-wake cycle.
Objective: To evaluate EC levels in the CSF of untreated narcoleptic patients to test whether ECs are dysregulated in Narcolepsy Type 1 (NT1) and Type 2 (NT2).
Methods: We compared CSF Anandamide (AEA), 2-Arachidonoylglycerol (2-AG) and orexin in narcoleptic drug-naïve patients and in a sample of healthy subjects.
Results: We compared NT1 (n=6), NT2 (n=6), and healthy controls (n=6). We found significantly reduced AEA levels in NT1 patients compared to both NT2 and controls. No differences were found between AEA levels in NT2 versus controls and between 2-AG levels in all groups, although a trend toward a decrease in NT1 was evident. Finally, the CSF AEA level was related to CSF orexin levels in all subjects.
Conclusion: We demonstrated that the EC system is dysregulated in NT1.
[http://dx.doi.org/10.2174/1871527317666180314115623] [PMID: 29542425]
[http://dx.doi.org/10.2174/1871527318666190131121827] [PMID: 30706796]
[http://dx.doi.org/10.1111/j.1528-1167.2009.02334.x] [PMID: 19817812]
[http://dx.doi.org/10.1016/j.pbb.2013.04.006] [PMID: 23603032]
[http://dx.doi.org/10.3390/ph10040079] [PMID: 28991183]
[http://dx.doi.org/10.2174/1871527316666170223161908] [PMID: 28240187]
[http://dx.doi.org/10.1111/bph.14440] [PMID: 29981240]
[http://dx.doi.org/10.1146/annurev-neuro-070815-014038] [PMID: 27023732]
[http://dx.doi.org/10.1016/j.pharmthera.2017.02.041] [PMID: 28232276]
[http://dx.doi.org/10.2174/1871527316666170413101839] [PMID: 28412921]
[http://dx.doi.org/10.2174/187152731605170810115956] [PMID: 28847308]
[http://dx.doi.org/10.2174/1871527316666170413105421] [PMID: 28412919]
[http://dx.doi.org/10.2174/1871527318666181227123924] [PMID: 30588889]